Strengthening Transplantation Effects of Bone Marrow Mononuclear Cells With Atorvastatin in Myocardial Infarction
NCT ID: NCT00979758
Last Updated: 2018-01-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
100 participants
INTERVENTIONAL
2009-01-31
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Transplantation Efficacy of Autologous Bone Marrow Mesenchymal Stem Cells With Intensive Atorvastatin in AMI Patients
NCT03047772
Bone Marrow Mesenchymal Stem Cells Transfer in Patients With ST-segment Elevation Myocardial Infarction
NCT04421274
Stem Cell Therapy to Improve Myocardial Function in Patients Undergoing Coronary Artery Bypass Grafting (CABG)
NCT00395811
Clinical Study of Hypoxia-Stressed Bone Marrow Mononuclear Cell Transplantation to Treat Heart Diseases
NCT01234181
Safety and Efficacy of Bone Marrow Cell Transplantation in Humans Myocardial Infarction
NCT00437710
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Heart function tests may include the following:
1. Electrocardiogram (EKG) evaluates the electrical activity of the heart. Electrodes placed on the chest transmit information from the heart to a machine.
2. Echocardiogram (Echo) is an ultrasound test that uses sound waves to create an image of the heart and examine the function of the heart chambers and valves.
3. Gated acquisition scan is a nuclear medicine test that uses a small amount of radioactive chemical injected into a vein. A special scanner creates an image of the heart for examining the beating motion of the muscle.
4. MRI evaluates function of the heart chambers the beating motion of the muscle.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atorvastatin
Atorvastatin routine dose
Atorvastatin and mononuclear cells transplantation
Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation
Intensive Atorvastatin
Atorvastatin Intensive dose
Atorvastatin and mononuclear cells transplantation
Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation
Atorvastatin+Transplantation
Atorvastatin routine dose+ Mononuclear cells Transplantation
Atorvastatin and mononuclear cells transplantation
Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation
Intensive Atorvastatin+Transplantation
Atorvastatin intensive dose+ Mononuclear cells Transplantation
Atorvastatin and mononuclear cells transplantation
Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin and mononuclear cells transplantation
Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. At most 2 months since last episode of ST-elevation myocardial infarction.
3. Left ventricular ejection fraction \>=20% \<=45% based on coronary angiography or echocardiography.
Exclusion Criteria
2. Patients with normal left ventricular function.
3. Patients with mechanical complications of myocardial infarction.
4. Patients with a malignant tumor.
5. Patients with infection disease.
6. Less than 6 months since last episode of stroke.
7. Patients with hematological disease (leukemia, myeloproliferative disease, or myelodysplastic syndromes).
8. AST (GOT) exceeding 100 IU/L or ALT (GPT) exceeding 100 IU/L.
9. Leukocytes less than 4,000/µL or exceeding 10,000/µL.
10. Platelets less than 100,000/µL.
11. Hemoglobin less than 10 g/dL.
12. Pregnant or nursing patients, those who may be pregnant, or those who plan on becoming pregnant before the end of the study period.
13. Any other reason that the Clinical Supervisors or Clinical Researchers may have for considering a case unsuitable for the study.
30 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese Academy of Medical Sciences, Fuwai Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yuejin Yang
Vice president of Fuwai hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yang yuejin, Doctor
Role: STUDY_DIRECTOR
Chinese Academy of Medical Sciences, Fuwai Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fuwai Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Yang YJ, Qian HY, Song L, Geng YJ, Gao RL, Li N, Wang H, Tian XQ, Huang J, Huang PS, Xu J, Shen R, Lu MJ, Zhao SH, Wu WC, Wu Y, Zhang J, Qian J, Xu JY, Xiong YY. Strengthening effects of bone marrow mononuclear cells with intensive atorvastatin in acute myocardial infarction. Open Heart. 2020 May;7(1):e001139. doi: 10.1136/openhrt-2019-001139.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Fuwai Hospital 2009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.